DrugPatentWatch Database Preview
Celgene Company Profile
Email this page to a colleague
» See Plans and PricingWhat is the competitive landscape for CELGENE, and what generic alternatives to CELGENE drugs are available?
CELGENE has seven approved drugs.
There are forty-one US patents protecting CELGENE drugs.
There are five hundred and forty-four patent family members on CELGENE drugs in forty-eight countries and fifteen supplementary protection certificates in ten countries.
Summary for Celgene
| International Patents: | 544 |
| US Patents: | 41 |
| Tradenames: | 7 |
| Ingredients: | 7 |
| NDAs: | 7 |
| Patent Litigation for Celgene: | See patent lawsuits for Celgene |
| PTAB Cases with Celgene as patent owner: | See PTAB cases with Celgene as patent owner |
Drugs and US Patents for Celgene
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Celgene | REVLIMID | lenalidomide | CAPSULE;ORAL | 021880-003 | Jun 29, 2006 | RX | Yes | No | 8,315,886 | Start Trial | Start Trial | ||||
| Celgene | REVLIMID | lenalidomide | CAPSULE;ORAL | 021880-001 | Dec 27, 2005 | RX | Yes | No | 7,189,740 | Start Trial | Start Trial | ||||
| Celgene | POMALYST | pomalidomide | CAPSULE;ORAL | 204026-001 | Feb 8, 2013 | RX | Yes | No | 6,561,977 | Start Trial | Start Trial | ||||
| Celgene | REVLIMID | lenalidomide | CAPSULE;ORAL | 021880-005 | Dec 21, 2011 | RX | Yes | No | 8,626,531 | Start Trial | Start Trial | ||||
| Celgene | REVLIMID | lenalidomide | CAPSULE;ORAL | 021880-003 | Jun 29, 2006 | RX | Yes | No | 8,492,406 | Start Trial | Start Trial | ||||
| Celgene | POMALYST | pomalidomide | CAPSULE;ORAL | 204026-004 | Feb 8, 2013 | RX | Yes | Yes | 8,315,886 | Start Trial | Start Trial | ||||
| Celgene | REVLIMID | lenalidomide | CAPSULE;ORAL | 021880-004 | Jun 29, 2006 | RX | Yes | Yes | Start Trial | Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Celgene
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Celgene | THALOMID | thalidomide | CAPSULE;ORAL | 020785-004 | Jan 10, 2007 | 8,204,763 | Start Trial |
| Celgene | REVLIMID | lenalidomide | CAPSULE;ORAL | 021880-006 | Jun 5, 2013 | 6,281,230 | Start Trial |
| Celgene | REVLIMID | lenalidomide | CAPSULE;ORAL | 021880-006 | Jun 5, 2013 | 8,288,415 | Start Trial |
| Celgene | POMALYST | pomalidomide | CAPSULE;ORAL | 204026-002 | Feb 8, 2013 | 8,158,653 | Start Trial |
| Celgene | REVLIMID | lenalidomide | CAPSULE;ORAL | 021880-006 | Jun 5, 2013 | 6,561,976 | Start Trial |
| Celgene | POMALYST | pomalidomide | CAPSULE;ORAL | 204026-003 | Feb 8, 2013 | 8,158,653 | Start Trial |
| Celgene | REVLIMID | lenalidomide | CAPSULE;ORAL | 021880-003 | Jun 29, 2006 | 6,045,501 | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for CELGENE drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Capsules | 1 mg, 2 mg, 3 mg and 4 mg | ➤ Subscribe | 2017-02-08 |
| ➤ Subscribe | Capsules | 5 mg, 10 mg and 15 mg | ➤ Subscribe | 2010-08-30 |
| ➤ Subscribe | Capsules | 50 mg and 100 mg | ➤ Subscribe | 2006-12-18 |
| ➤ Subscribe | Capsules | 150 mg | ➤ Subscribe | 2014-02-03 |
| ➤ Subscribe | Capsules | 25 mg | ➤ Subscribe | 2010-07-12 |
| ➤ Subscribe | Capsules | 2.5 mg and 20 mg | ➤ Subscribe | 2016-07-12 |
| ➤ Subscribe | Capsules | 200 mg | ➤ Subscribe | 2006-09-25 |
| ➤ Subscribe | Injection | 10 mg/vial | ➤ Subscribe | 2013-11-05 |
International Patents for Celgene Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Chile | 2007002218 | Start Trial |
| European Patent Office | 2406389 | Start Trial |
| Japan | 2009510171 | Start Trial |
| Poland | 3042659 | Start Trial |
| African Intellectual Property Organization (OAPI) | 13250 | Start Trial |
| Brazil | PI0410306 | Start Trial |
| Spain | 2728776 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Celgene Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2105135 | C20150005 00140 | Estonia | Start Trial | PRODUCT NAME: POMALIDOMIID;REG NO/DATE: EU/1/13/850 08.08.2013 |
| 2105135 | 92642 | Luxembourg | Start Trial | PRODUCT NAME: POMALIDOMIDE ET SES SELS, SOLVATES, HYDRATES OU STEREOISOMERES PHARMACEUTIQUEMENT ACCEPTABLES QUI EN DERIVENT (IMNOVID); FIRST REGISTRATION DATE: 20130805 |
| 0620232 | 08C0036 | France | Start Trial | PRODUCT NAME: THALIDOMIDE; REGISTRATION NO/DATE: EU/1/08/443/001 20080416 |
| 0688211 | 08C0036 | France | Start Trial | PRODUCT NAME: THALIDOMIDE; REGISTRATION NO/DATE: EU/1/08/443/001 20080416 |
| 2105135 | CA 2015 00006 | Denmark | Start Trial | PRODUCT NAME: POMALIDOMID OG FARMACEUTISK ACCEPTABLE SALTE, SOLVATER, HYDRATER ELLER STEREOISOMERER HERAF; REG. NO/DATE: EU/1/13/850 20130805 |
| 0925294 | SPC/GB07/047 | United Kingdom | Start Trial | PRODUCT NAME: LENALIDOMIDE (COMMON NAME) 1-OXO-2-(2,6-DIOXOPIPERIDIN-3-YL)-4-AMINOSOINDOLINE OPTIONALLY IN THE FORM OF AN ACID ADDITION SALT; REGISTERED: UK EU/1/07/391/001 20070619; UK EU/1/07/391/002 20070619; UK EU/1/07/391/003 20070619; UK EU/1/07/391/004 20070619 |
| 2105135 | 300717 | Netherlands | Start Trial | PRODUCT NAME: POMALIDOMIDE EN FARMACEUTISCH AANVAARDBARE ZOUTEN, SOLVATEN, HYDRATEN OF STEREOISOMEREN DAARVAN; REGISTRATION NO/DATE: EU/1/13/850 20130805 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
